Julianne Jett, PhD

• Texas State University, BS, Psychology and Biology 
• Univeristy of Texas Health Science Center San Antonio, PhD, Neurosience and Pharmacology 

• Research Coordinator, University of Texas Health Science Center San Antonio 
• Graduate Teaching Assistant, University of Texas Health Science Center San Antonio  
• Postdoctoral Research Assistant, Washington State Univeristy 
• Research Assistant Professor, Washington State Univeristy 

Dr. Julianne Jett received her doctorate in neuroscience and pharmacology from the University of Texas Health San Antonio, where she investigated mechanisms underlying stress-induced prefrontal cortex dysfunction in rats. She then transitioned to clinical research during her postdoctoral training with Promoting Research Initiatives in Substance Use and Mental Health (PRISM) Collaborative at Washington State University. Her postdoctoral studies used alcohol biomarkers, like ethyl glucuronide and phosphatidylethanol, to rigourously study drinking patterns in individuals with alcohol use disorder, and to assess the efficacy of contingency managment models in this population. Currently, Dr. Jett is a Research Assistant Professor in the Department of Community and Behavioral Health at Washington State University. Her research program investigates whether Addiction Neuroclinical Assessment variables (cognition, negative emotionality, and incentive salience) are associated with patterns of alcohol consumption, predict treatment outcomes, or change as a consequence of treatment. This work utilizes biomarkers to objectively measure stress response and alcohol consumption in individuals with alcohol use disorders.

 

• Mitte Research grant, 2006
• Psi Chi Research grant, 2007
• Translational Science Training Fellowship, 2012
• Alcohol and Drug Abuse Research Program Award, 2021

1. Jett JD, Beck R, Tyutyunnyk D, Sanchez J, Weeks DL, Lopez-Cruzan M, Kriegel L, Ginsburg BC, Cabassa L, Javors MA, Hill-Kapturczak N, McDonell M. Feasibility of a telehealth-based contingency management intervention for alcohol use disorders using the phosphatidylethanol (PEth) alcohol biomarker: A pilot randomized trial. The American Journal of Drug and Alcohol Abuse. 2024; 50(2):162-172. PMCID: PMC11228813

2. Kriegel LS, Hampilos K, Weybright E, Weeks DL, Jett J, Hill L, Roll J, McDonell M. Addressing the spectrum of opioid misuse prevention, treatment, and recovery in rural [blinded state] communities: Provider identified barriers and needs. The Community and Mental Health Journal. 2024: 60(3):600-607

3. Lu T, Parent S, Chaytor N, Amiri S, Palmer K, McPherson S, Jett J, Reis R, McDonell MG, Murphy SM. Budget impact tool for implimenting contingency management for co-occurring alcohol use disorders and seriou smental illness. Journal of Psychiatry Services. 2024; 75(4):326-332. PMCID: PMC10984796

4. Jett JD, Beck R, Tyutyunnyk D, Sanchez J, Lopez-Cruzan M, Ginsburg BC, McPherson SM, Javors MA, McDonell MG, Hill-Kapturczak N. Validation of the quantification of phosphotidylethanol (PEth) 16:0/18:1 concentrations in TASSO-M20 Devices. Alcohol Clin Exp Res. 2023; 47(4):748-755. PMCID: PMC10149590.

5. Jett JD, Kordas G, Parent S, Keshtkar M, Shin R, King P, McPherson SM, Ries R, Roll JM, McDonell MG, Chaytor N. Assessing clinically significant cognitive impairment using the NIH Toolbox in individuals with co-occurring serious mental illness and alcohol use disorder. J Addict Med. 2023; 17(3): 305-311. PMCID: PMC10164836.

6. Fraser ER, Hill-Kapturczak N, Jett J, Beck R, Oluwoye O, Kriegel LS, Alcover KC, McPherson S, Cabassa LJ, Javors M, McDonell MG. Mixed-methods trial of a phosphatidylethanol-based contingency management intervention to initiate and maintain alcohol abstinence in formerly homeless adults with alcohol use disorders. Contemp Clin Trials Commun, 2021; 22: 1-9. PMCID: PMC7973861.

7. Jett JD, Bulin SE, Hatherall LC, McCartney CM, Morilak DA. Cognitive deficits induced by chronic unpredictable stress are associated with impaired glutamate transmission in the rat medial prefrontal cortex. Neuroscience, 2017; 346: 284-97. PMCID: PMC5344040.

8. Jett JD, Boley AM, Girotti M, Shah A, Lodge DJ, Morilak DA. Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology, 2015; 232(17): 3123-33. PMCID: PMC4536154.

9. Heisler JM, Morales J, Donegan J, Jett JD, Redus L, O'Conner J. The attentional set-shifting task: A measure of cognitive flexibility in mice. Journal of Visualized Experiments, 2015; 4(96): e51944. PMCID: PMC4354620

10. Jett JD, Morilak DA. Too much of a good thing: Blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental cognitive effects of chronic stress Neuropsychopharmacology, 2013; 38(4): 585-595. PMICD: PMC3572455.

11. Bondi CO, Jett JD, Morilak DA. Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by a₁-adrenergic receptors in medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry, 2010; 34(6): 913-23. PMCID: PMC2910206.

12. Lapiz-Bluhm MDS, Bondi CO, Doyen J, Rodriguez G, Bedard-Arana T, Morilak DA. Behavioral assasys to model cogntive and affective dimensions of depression and anxiety in rats. Journal of Neuroendocrinology. 20(10): 1115-1137. PMCID: PMC4354620.